MannKind to Present at the JMP Securities Life Sciences Conference
June 12 2019 - 9:00AM
MannKind Corporation (NASDAQ: MNKD), a company
focused on the development and commercialization of inhaled
therapeutic products for patients with diseases such as diabetes
and pulmonary arterial hypertension, announced today that it will
be featured as a presenting company at the JMP Securities Life
Sciences Conference at 9:00 AM (ET) on June 19, 2019. The
conference is being held at The St. Regis in New York.
Michael Castagna, Chief Executive Officer, of
MannKind Corporation, will provide an overview of the Company's
business during the live presentation. Steven B. Binder,
Chief Financial Officer, will participate in one-on-one meetings
with investors who are registered to attend the
conference.
The presentation will be webcast live.
Interested parties can access a link to the live webcast of the
presentation from the News & Events section of the Company's
website at http://www.mannkindcorp.com. The webcast replay
will remain available for 14 days following the live
presentation.
About MannKind
CorporationMannKind Corporation (NASDAQ:MNKD) focuses
on the development and commercialization of inhaled therapeutic
products for patients with diseases such as diabetes and pulmonary
arterial hypertension. MannKind is currently
commercializing Afrezza® (insulin human) Inhalation Powder, the
Company's first FDA-approved product and the only orally
inhaled ultra rapid-acting mealtime insulin in the United
States, where it is available by prescription from pharmacies
nationwide. MannKind is headquartered in Westlake
Village, California, and has a state-of-the art manufacturing
facility in Danbury, Connecticut. The Company also employs
field sales and medical representatives across the U.S. For further
information, visit www.mannkindcorp.com.
Company Contact:Rose AlinayaInvestor
Relations818-661-5000ir@mannkindcorp.com
Source: MannKind Corporation
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Mar 2024 to Apr 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Apr 2023 to Apr 2024